← Human Trials & Peer-Reviewed Studies
Effects of "Essential AD2" Supplement on Blood Acetaldehyde Levels in Individuals Who Have Aldehyde Dehydrogenase (ALDH2) Deficiency.
Plain-language guide to PMID 29509552 (2019): open-label and placebo-controlled clinical trial of Copper (Supplement).
Key Facts
- PMID
- 29509552
- Journal
- American journal of therapeutics
- Year
- 2019
- Study type
- Clinical Trial
- Authors
- Fujioka K et al. (2 authors)
- DOI
- 10.1097/MJT.0000000000000744
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Copper (Supplement), published as a clinical trial.
It is estimated that 1 billion people in the world have a point mutation in the gene encoding the aldehyde dehydrogenase 2 (ALDH2) enzyme, the primary enzyme responsible for the metabolism of acetaldehyde.
The presence of this mutation is called ALDH2 deficiency.
Who Took Part
By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.
The study consisted of 12 subjects genotyped to be heterozygous for the ALDH2 gene mutation.
How the Study Was Run
In design terms this was an open-label, placebo-controlled and pilot study.
Being open-label, the Copper (Supplement) study did not mask who received what.
A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.
It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.
What Was Measured
It is estimated that 1 billion people in the world have a point mutation in the gene encoding the aldehyde dehydrogenase 2 (ALDH2) enzyme, the primary enzyme responsible for the metabolism of acetaldehyde.
Because of limited ability to metabolize acetaldehyde, individuals with ALDH2 deficiency experience elevated levels of blood acetaldehyde after exposure to various common sources such as recreational alcohol.
Topics PubMed links to this paper include Acetaldehyde, Alcohol Drinking, Aldehyde Dehydrogenase, Mitochondrial, Asian People, Dietary Supplements, Ethanol and Healthy Volunteers.
What This Means in Plain Language
The paper is an open-label, placebo-controlled and pilot study of Copper (Supplement).
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2019 (American journal of therapeutics), a journal based in United States.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.